Is Procter & Gamble Health a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Procter & Gamble Health Ltd is a good quality company .

Is Procter & Gamble Health undervalued or overvalued?

The key valuation ratios of Procter & Gamble Health Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Procter & Gamble Health share price return in the past 10 years?

Procter & Gamble Health Ltd share price has appreciated 20.6% annually (CAGR) over the past ten years.

Is Procter & Gamble Health a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Procter & Gamble Health Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

What is the P/E ratio of Procter & Gamble Health?

The latest standalone P/E ratio of Procter & Gamble Health as of 21-Nov-2024 is 39.15.

What is the P/B ratio of Procter & Gamble Health?

The latest standalone P/B ratio of Procter & Gamble Health as of 21-Nov-2024 is 13.93.

Procter & Gamble Health Ltd - Stock Valuation and Financial Performance

Name: Procter & Gamble Health
Brand: Procter & Gamble Health

BSE: 500126 | NSE: PGHL | Pharmaceuticals & Drugs | Small Cap

Place order

Procter&Gamble Healt Share Price

₹5,124.10 -10.85 -0.21%
as on 21-Nov'24 16:59

10 Year X-Ray of Procter&Gamble Healt:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Dec'14	Dec'15	Dec'16	Dec'17	Dec'18	Jun'20	Jun'21	Jun'22	Jun'23	Jun'24	TTM
ROCE % ⓘ	12.4%	14.5%	18.4%	14.2%	13.9%	29%	29.1%	38.5%	46.1%	42.5%	-
Value Creation Index ⓘ	-0.1	0.0	0.3	0.0	0.0	1.2	1.2	1.9	2.4	2.2	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	867	940	993	698	849	904	1,009	1,114	1,230	1,151	1,160
Sales YoY Gr.	-	8.3%	5.7%	-29.7%	21.6%	6.5%	11.6%	10.5%	10.3%	-6.4%	-
Adj EPS ⓘ	25.5	31.7	46.6	28.8	58.1	102.2	107.1	116.5	137.8	129.7	131.2
YoY Gr.	-	24.2%	47.1%	-38.3%	102.1%	75.9%	4.8%	8.8%	18.3%	-5.9%	-
BVPS (₹) ⓘ	333.9	356.4	399.9	441.7	927.8	363.2	421.6	367	447.6	319.1	368.7
Adj Net Profit ⓘ	42.4	52.6	77.4	47.8	96.5	170	178	193	229	215	218
Cash Flow from Ops. ⓘ	5	83.5	107	53.7	-130	157	247	170	236	228	-
Debt/CF from Ops. ⓘ	0	0	0	0	0	0	0	0	0	0	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	3.2%	6.3%	4.5%	-6.4%
Adj EPS ⓘ	19.8%	17.4%	6.6%	-5.9%
BVPSⓘ	-0.5%	-19.2%	-8.9%	-28.7%
Share Price	20.6%	3.7%	0.8%	-0.8%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Dec'14	Dec'15	Dec'16	Dec'17	Dec'18	Jun'20	Jun'21	Jun'22	Jun'23	Jun'24	TTM
Return on Equity % ⓘ	7.9	9.2	12.3	6.8	8.5	20.8	22.1	29.3	33.5	33.4	38.1
Op. Profit Mgn % ⓘ	6.8	9	11.7	10.1	17	23.4	24.5	24.1	26.4	26.6	28.6
Net Profit Mgn % ⓘ	4.9	5.6	7.8	6.8	11.4	18.8	17.6	17.4	18.6	18.7	18.8
Debt to Equity ⓘ	0	0	0	0	0	0	0	0	0	0	-
Working Cap Days ⓘ	274	381	367	503	486	346	491	438	423	470	98
Cash Conv. Cycle ⓘ	85	82	66	88	49	12	-3	-22	-31	-33	63

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 38.10%

Sales growth has been subdued in last 3 years 4.50%

Net Profit has been subdued in last 3 years 6.60%

Sales growth is not so good in last 4 quarters at -6.07%

Latest Financials - Procter & Gamble Health Ltd.

	Standalone	Consolidated
TTM EPS (₹)	131.2	-
TTM Sales (₹ Cr.)	1,160	-
BVPS (₹.) ⓘ	368.7	-
Reserves (₹ Cr.) ⓘ	595	-
P/BV ⓘ	13.93	-
PE ⓘ	39.15	-

From the Market
52 Week Low / High (₹)	4640.30 / 5835.95
All Time Low / High (₹)	114.00 / 7499.95
Market Cap (₹ Cr.)	8,524
Equity (₹ Cr.)	16.6
Face Value (₹)	10
Industry PE ⓘ	43

Management X-Ray of Procter&Gamble Healt:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Procter&Gamble Healt

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Procter&Gamble Healt

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Dec'14	Dec'15	Dec'16	Dec'17	Dec'18	Jun'20	Jun'21	Jun'22	Jun'23	Jun'24
Sales	867	940	993	698	849	1,356	1,009	1,114	1,230	1,151
Operating Expenses ⓘ	809	856	877	628	705	1,042	763	847	905	845
Manufacturing Costs	84	86	73	81	85	140	139	147	139	122
Material Costs	405	437	412	237	269	431	312	340	362	331
Employee Cost	114	123	154	110	131	183	154	168	206	215
Other Costs ⓘ	206	210	238	200	220	287	158	193	198	178
Operating Profit ⓘ	59	83	116	71	144	314	246	268	325	306
Operating Profit Margin (%)	6.8%	8.9%	11.6%	10.1%	17.0%	23.2%	24.4%	24.0%	26.4%	26.6%
Other Income ⓘ	20	23	24	30	28	70	18	13	18	16
Interest ⓘ	0	0	0	0	0	0	1	0	1	1
Depreciation ⓘ	13	23	25	19	21	29	30	27	28	27
Exceptional Items ⓘ	0	0	0	17	7	0	0	0	0	-20
Profit Before Tax ⓘ	67	83	115	99	158	355	233	253	314	273
Tax ⓘ	23	30	36	38	56	101	56	61	85	72
Profit After Tax	43	54	79	61	102	254	177	193	229	201
PAT Margin (%)	5.0%	5.7%	8.0%	8.7%	12.0%	18.7%	17.5%	17.3%	18.7%	17.5%
Adjusted EPS (₹)	26.0	32.3	47.7	36.8	61.3	153.1	106.5	116.0	138.2	121.1
Dividend Payout Ratio (%)	23%	23%	23%	41%	718%	150%	122%	45%	69%	215%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Dec'14	Dec'15	Dec'16	Dec'17	Dec'18	Jun'20	Jun'21	Jun'22	Jun'23	Jun'24
Equity and Liabilities
Shareholders Fund	554	592	664	733	1,540	904	700	609	743	530
Share Capital ⓘ	17	17	17	17	17	17	17	17	17	17
Reserves ⓘ	538	575	647	717	1,524	888	683	593	726	513
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	0	0	0	0	0	0	0	0	0	0
Long Term Debt	0	0	0	0	0	0	0	0	0	0
Short Term Debt	0	0	0	0	0	0	0	0	0	0
Trade Payables	44	66	75	83	91	124	179	172	237	167
Others Liabilities ⓘ	606	868	624	699	951	1,084	1,099	1,157	1,253	1,307
Total Liabilities ⓘ	1,204	1,525	1,363	1,516	2,583	2,112	1,978	1,938	2,233	2,004
Fixed Assets
Gross Block	232	271	144	192	186	200	215	241	263	223
Accumulated Depreciation	122	140	25	51	61	102	114	131	121	97
Net Fixed Assetsⓘ	110	132	119	140	124	98	101	110	142	127
CWIP ⓘ	28	7	30	9	17	21	39	41	32	6
Investmentsⓘ	24	42	28	70	0	0	0	0	0	0
Inventories	177	167	164	158	113	134	118	115	135	109
Trade Receivables	105	127	107	123	66	95	60	83	116	85
Cash Equivalents	164	188	279	278	1,243	639	469	325	440	244
Others Assetsⓘ	597	863	636	738	1,018	1,124	1,191	1,264	1,368	1,433
Total Assets ⓘ	1,204	1,525	1,363	1,516	2,583	2,112	1,978	1,938	2,233	2,004

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Dec'14	Dec'15	Dec'16	Dec'17	Dec'18	Jun'20	Jun'21	Jun'22	Jun'23	Jun'24
Cash Flow From Operating Activity ⓘ	5	83	107	54	-130	235	247	170	236	228
PBT ⓘ	67	83	115	152	1,138	355	233	253	314	273
Adjustment ⓘ	21	16	15	8	-914	-12	41	27	41	52
Changes in Working Capital ⓘ	-49	16	30	-47	-50	-6	41	-47	-30	-12
Tax Paid ⓘ	-34	-32	-53	-60	-304	-102	-68	-64	-90	-85
Cash Flow From Investing Activity ⓘ	11	-68	-75	-48	1,270	165	-32	-26	-22	-7
Capex	-40	-45	-32	-10	-19	-23	-51	-38	-38	-22
Net Investments	32	-39	-59	-57	214	124	0	0	0	0
Others ⓘ	19	16	16	20	1,075	64	19	12	16	15
Cash Flow From Financing Activityⓘ	-17	-12	-15	-22	-30	-883	-387	-289	-98	-418
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Dividend Paid ⓘ	-14	-10	-12	-18	-25	-733	-382	-284	-94	-415
Others ⓘ	-2	-2	-3	-4	-5	-150	-5	-5	-5	-3
Net Cash Flow ⓘ	-1	4	17	-16	1,109	-483	-172	-145	116	-197

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Dec'14	Dec'15	Dec'16	Dec'17	Dec'18	Jun'20	Jun'21	Jun'22	Jun'23	Jun'24
Ratios
ROE (%)	8.02	9.35	12.61	8.74	8.95	20.79	22.04	29.41	33.94	31.58
ROCE (%)	12.36	14.54	18.35	14.16	13.9	29.01	29.08	38.45	46.07	42.52
Asset Turnover Ratio	0.91	0.71	0.71	0.49	0.41	0.58	0.49	0.6	0.64	0.59
PAT to CFO Conversion(x)	0.12	1.54	1.35	0.89	-1.27	0.93	1.4	0.88	1.03	1.13
Working Capital Days
Receivable Days	38	43	41	59	41	22	28	22	27	29
Inventory Days	67	64	59	83	58	33	46	36	34	35
Payable Days	35	45	61	118	116	91	177	189	206	223

Procter & Gamble Health Ltd Stock News

Procter & Gamble Health Ltd FAQs

What is the share price of Procter&Gamble Healt?

Company share prices are keep on changing according to the market conditions. The closing price of Procter&Gamble Healt on 21-Nov-2024 16:59 is ₹5,124.1.

What is the market cap of Procter&Gamble Healt?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Nov-2024 16:59 the market cap of Procter&Gamble Healt stood at ₹8,523.7.

What is the P/E ratio of Procter&Gamble Healt?

The latest P/E ratio of Procter&Gamble Healt as of 21-Nov-2024 16:59 is 39.15.

What is the P/B ratio of Procter&Gamble Healt?

The latest P/B ratio of Procter&Gamble Healt as of 21-Nov-2024 16:59 is 13.93.

What is the 52-week high and low of Procter&Gamble Healt?

The 52-week high of Procter&Gamble Healt is ₹5,836 and the 52-week low is ₹4,640.3.

What is the TTM revenue of Procter&Gamble Healt?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Procter&Gamble Healt is ₹1,160 ( Cr.) .

About Procter & Gamble Health Ltd

Procter & Gamble Health Limited (formerly Merck Limited) was set up in India as one of Merck’s Asian subsidiaries in 1967. It was also the first Merck Group Company to go public in the year 1981. Till 2018, the Company was operating in all businesses included in the pharmaceuticals and chemicals businesses in the country.

On December 1st, 2018, P&G successfully completed the acquisition of Merck’s Consumer Health business further to approval of all relevant regulatory authorities and the fulfilment of other customary closing conditions. Procter & Gamble Overseas India B.V. now holds 51.81% of the share capital in Merck Limited, while the remaining 48.19% is traded on the Bombay Stock Exchange Ltd. and National Stock Exchange of India Ltd.

Currently, Procter & Gamble Health Limited (formerly Merck Limited) is one of India’s largest VMS Companies manufacturing and marketing over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life. Its trusted products are household names in India protecting and supporting millions of people at every stage of life. With a strong portfolio of brands backed by science and trusted by doctors, pharmacists and consumers, Procter & Gamble Health Limited combines the best of P&G and Legacy Merck’s Consumer Health capabilities and cultures. Together we are working towards leveraging our combined expertise to develop categories and brands that meet today’s needs and tomorrow’s opportunities.

Situated at Usgaon, Goa, the company’s Manufacturing Site has grown from a small Vitamin E producing unit to a big composite plant manufacturing pharma and chemical products.

Business area of the company

Till 2018, the Company was operating in all businesses included in the pharmaceuticals and chemicals businesses in the country. The company is one of India’s largest VMS Companies manufacturing and marketing over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life. Its trusted products are household names in India protecting and supporting millions of people at every stage of life.

Brands of the company

Neurobion
Evion
Seven Seas
Nasivion
Polybion
Livogen

Awards and achievements

2015-16: Merck Goa plant was awarded 1st prize in safety called “Gomant Sarvochcha Suraksha Puraskar”. This is consecutive 2nd time Merck Goa plant bagged 1st prize in safety. Prior to that Merck Goa plant bagged 2nd prize in safety “Gomant Uchcha Suraksha Puraskar” for two consecutive years.
2016-17: Consumer activation done for Neurobion under ‘True Heroes’ campaign won laurels at the Global level to receive President’s Award in 2017.
2017-18: Nasivion continued to be the Doctors’ trusted No. 1 Nasal Decongestant.
2019-20: Neurobion bagged three awards viz. Nicholas Hall Marketing Excellence Award; CIMS Trusted Brand of the Year; and ABP News Brand Excellence Award.